A supplemental application for Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) received FDA approval for efficacy on 2026-02-10. This approval, sponsored by Merck Sharp Dohme, signifies an expansion or modification of the drug's approved uses based on new efficacy data.
Background
Keytruda Qlex is a drug product containing pembrolizumab and berahyaluronidase alfa-pmph. Pembrolizumab is also known by the brand name Keytruda. This supplemental approval specifically pertains to the efficacy of the Keytruda Qlex formulation, indicating that the U.S. Food and Drug Administration has evaluated and confirmed its therapeutic benefits in a new or expanded context. The application was submitted by Merck Sharp Dohme.
What this means
The supplemental FDA approval for Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) for efficacy means that the agency has reviewed and accepted new clinical data supporting the drug's effectiveness. While the specific indication or patient population for this supplemental approval is not detailed in the provided information, such approvals are granted when a drug demonstrates a new clinical benefit. This could involve an expansion to new disease states, new stages of existing diseases, or new patient populations. For clinicians, this approval potentially broadens the therapeutic options available with Keytruda Qlex, allowing its use in additional settings where its efficacy has now been established according to regulatory standards. Patients may benefit from expanded access to this treatment for conditions where it has now shown proven efficacy.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA). The approval for supplemental application BLA 761467 S-2 for Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) was issued on 2026-02-10 and is publicly accessible on accessdata.fda.gov.